New hope for transplant patients: drug combo targets stubborn GVHD
NCT ID NCT07484113
First seen Mar 22, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This early-phase trial tests a drug called sarilumab in 10 adults with chronic graft-versus-host disease (cGVHD) that did not improve with the standard treatment belumosudil. The goal is to see if sarilumab is safe and tolerable as a rescue therapy. Participants will receive sarilumab alone, and researchers will monitor side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.